Home » Stocks » IDYA

IDEAYA Biosciences, Inc. (IDYA)

Stock Price: $16.85 USD 0.51 (3.12%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 489.82M
Revenue (ttm) 8.97M
Net Income (ttm) -40.14M
Shares Out 28.40M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE 4.65
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $16.85
Previous Close $16.34
Change ($) 0.51
Change (%) 3.12%
Day's Open 16.40
Day's Range 16.29 - 17.49
Day's Volume 1,476,717
52-Week Range 3.03 - 18.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 5 days ago

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of ...

PRNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...

PRNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...

PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of...

Zacks Investment Research - 1 month ago

IDEAYA Biosciences (IDYA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development o...

PRNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

Zacks Investment Research - 5 months ago

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -126.34% and -100.00%, respectively, for the quarter ended June 2020.

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

Zacks Investment Research - 5 months ago

IDEAYA Biosciences (IDYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 4, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of...

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of ...

InvestorPlace - 6 months ago

A high-profile partnership and a promising pipeline of oncology-focused treatments suggest favorable reward-versus-risk in IDYA stock. The post Target Breakthrough Science and Medicine with Id...

The Motley Fool - 6 months ago

Here's what pushed up shares of the highest-flying healthcare stocks.

Other stocks mentioned: CLDX, QDEL
The Motley Fool - 6 months ago

The development-stage drug developer is selling common stock to raise cash. It's a wise move.

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 17, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its com...

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common st...

Benzinga - 7 months ago

IDEAYA Biosciences (NASDAQ: IDYA) shares are trading higher on Tuesday, after the company, along with GSK, announced a partnership in Synthetic Lethality.

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif. and LONDON, June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethal...

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development o...

Zacks Investment Research - 7 months ago

IDEAYA (IDYA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 8, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of ...

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., May 19, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...

PRNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of...

About IDYA

IDEAYA Biosciences, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination de... [Read more...]

Industry
Biotechnology
IPO Date
May 23, 2019
CEO
Yujiro Hata
Employees
58
Stock Exchange
NASDAQ
Ticker Symbol
IDYA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is 24.56, which is an increase of 45.76% from the latest price.

Price Target
$24.56
(45.76% upside)
Analyst Consensus: Strong Buy